Medicine · Wednesday, October 28, 2026
Anthropic says Claude is working inside six drug programs
The File desk · Oct. 28, 2026, 6:31 a.m. ET
Partially confirmed1 primary sources
Status
Partially confirmed. Anthropic published this account on October 27, 2026. The partnerships and the company's own programs are as that page describes them. No regulator's result is in the post.
- ConfirmedThe page names six partner organizations and says Anthropic has started drug-discovery work of its own, including rare childhood forms of muscular dystrophy.
- UnverifiedNo approved medicine, and no clinical-trial result, is reported in the passage this desk read.
Anthropic said on Monday, October 27, 2026, that its scientists have spent the past several months inside real drug programs at six organizations, and that the company has started discovery work of its own.1
The partners named are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Generate’s project, as Anthropic describes it, is to rework CAR T-cell therapy—a cancer treatment used against blood cancers—so it might treat solid tumors. The company’s own work includes rare childhood forms of muscular dystrophy, and Anthropic says Claude handles much of the scientific and operational work there.1
None of that is an approved medicine. Anthropic says it is optimistic that some programs may produce drugs for food allergies, rare childhood diseases, and several forms of cancer, if the early trajectory holds. That is the company’s hope.1
Why it matters (Estimate). Estimate. Making a drug is slow because the hard parts are spread out: finding a target, designing a molecule, manufacturing it, writing the filings, and running the trials. Anthropic’s claim is that a model can sit in all of those steps, not only draw a first molecule. A patient does not receive a new drug from this post. What would change, if the company is right, is who does the middle of that work.
The page says the partnerships are also how the team sees where Claude fails, and that those failures have already led it to order specific improvements. It does not list the fixes.1
How we know
Notes
- 1.Anthropic, "Early progress on accelerating drug development with Claude," published Oct. 27, 2026. https://www.anthropic.com/research/early-progress-drug-development The page says scientists "engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group." It says the company has "started drug discovery efforts of our own, including programs for rare childhood forms of muscular dystrophy, where Claude handles much of the scientific and operational work." It says Generate Biomedicines is working to extend CAR T-cell therapy from blood cancers to solid tumors. It says the team is "optimistic that some may result in effective new medicines" for food allergies, rare childhood diseases, and several forms of cancer, "if their positive trajectories continue." It says the work has already led the team to prioritize specific model improvements.
What is still unknown or disputed
- Whether any program has a trial result. Not in the article passage this desk read.
- What the linked technical reports show. This desk read the article, not those reports.
- Which model changes the team ordered. The page says it ordered them and does not list them.
Primary sources
Every claim in this story is drawn from the documents below. If a fetch failed, that is recorded on the card.
Source 1
Early progress on accelerating drug development with Claude
Anthropic · October 27, 2026
Anthropic names six drug-development partners and says it has started its own programs, including rare childhood forms of muscular dystrophy.
https://www.anthropic.com/research/early-progress-drug-development